Familial amyotrophic lateral sclerosis (fALS) is caused by mutations in Cu/Zn-superoxide dismutase (SOD1), and SOD1 aggregation and calcium toxicity are involved in neuronal death. However, the effect of altered calcium homeostasis on the SOD1 aggregation is unknown. To investigate whether calcium triggers mutant SOD1 aggregation in vitro, human mutant SOD1 (G93A) was transfected into motor neuronal cell line (VSC 4.1 cells). These cells were then treated with calcium ionophore A23187 or agents that induce intracellular calcium release like cyclic ADP ribose, ryanodine or thapsigargin. A23187 was found to increase mutant SOD1 aggregation and neuronal nitric oxide synthase (nNOS) expression. Moreover, the NOS inhibitor (L-NAME) and a NO-dependent cyclic GMP cascade inhibitor (ODQ) reduced SOD1 aggregation, whereas an exogenous NO donor (GSNO) increased mutant SOD1 aggregation, which was also prevented by NOS or cGMP cascade inhibitor. Our data demonstrate that calcium-influx increases SOD1 aggregation by upregulating NO in cultured motor neuronal cells.
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that causes loss of motor neurons in spinal cord, brain stem, and motor cortex. Moreover, one fifth of familial ALS (fALS) cases are associated with mutations in the gene encoding free-radical scavenging enzyme Cu/Zn superoxide dismutase (SOD1) (Rosen et al., 1993) , and SOD1 protein aggregation mediates motor neuronal degeneration in ALS (Cleveland, 1999) . In addition, SOD1 aggregates have been observed in the neurons or astrocytes of transgenic mice expressing human mutant SOD1 (Bruijn et al., 1998) , and Lewy body-like hyaline inclusions, containing SOD1 as a major component, were observed in fALS patients (Shibata et al., 1996) . It has also been reported that mutant SOD1 aggregation triggers cytochrome c release, and that this release leads to caspase-dependent cell death (Takeuchi et al., 2002) .
Glutamate-induced excitotoxicity has also been implicated in the pathophysiology of ALS and has been reported in mutant SOD1 transgenic mice (Choi, 1988; Van Den Bosch et al., 2006) . Spinal motoneuron excitotoxicity depends on calciumpermeable α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors, which are expressed in a subset of neurons, including spinal motoneurons (Kruman et al., 1999) . Moreover, the absence of the GluR2 subunit in AMPA receptor renders the receptor calcium permeable (Hollmann and Heinemann, 1994) , and reduced GluR2 mRNA editing efficiency and GluR2 subunit expression have been reported in motor neurons from human sporadic ALS patients (Kawahara et al., 2004) and from mutant SOD1 transgenic mice (Tortarolo et al., 2006) . As spinal motor neurons are less able to buffer calcium level increases, due to a lack of calcium-chelating proteins like parvalbumin and calbindin D28K, excessive calcium-permeable glutamate receptor activation results in an intracellular calcium overload and motor neuronal death (Alexianu et al., 1994; Shaw and Eqqett, 2000) . SOD1 mutation increases the vulnerability of motor neurons to excitotoxicity induced by altered calcium homeostasis (Kruman et al., 1999) . Moreover, increased intracellular calcium triggers calpain (Rami et al., 1997) and neuronal nitric oxide synthase (nNOS) activation. However, the effect of increased intracellular calcium on the formation of mutant SOD1 aggregates is unknown. In this study, we investigated the mechanisms by which altered intracellular calcium homeostasis contributes to the formation of mutant SOD1 aggregates in cultured motor neuronal cells.
Materials and Methods
Cell Culture 
Plasmid constructs and transfection
pcDNA 3.1 vectors (Invitrogen, Carlsbad, CA) containing cDNA encoding wild type (WT) or mutant (G93A) human SOD1 were gifts from Dr. Lawrence J. Hayward (University of Massachusetts, Boston). WT and G93A SOD1 cDNA were cloned into the BamHI and EcoRI sites of pcDNA3.1 vector. To induce the transient overexpressions of WT and G93A SOD1 protein, VSC4.1 cells were plated at 2 × 10 5 cells per well in 24-well plates (Falcon) containing coverslips (Fisher Scientific, Pittsburgh, PA) coated with poly-L-ornithine. 5 µg plasmid DNAs of the WT or G93A SOD1 were mixed with serum free media containing 25 µl of Superfect (Qiagen, Valencia, CA), and incubated at room temperature for 10 min.
After 3 h of treatment, media were replaced with fresh culture medium. Transfection efficiencies fell in the range 50-60%.
Calcium ionophore, intracellular calcium releasers, NO, and other agents treatment
To investigate the effects of calcium influx on the formation of aggregates, 1 µM of calcium mobilizer (4-bromo-calcium ionophore A23187, Sigma) was added to culture medium 24 h after transient transfection with the cDNAs of WT or G93A SOD1. In addition, other intracellular calcium release agents, i.e., 10 µM cyclic ADP ribose, 10 nM ryanodine, or 10 µM thapsigargin were also added to the transfected cells. In order to determine the effects of exogenous nitric oxide (NO), 200 µM S-nitrosoglutathione (GSNO, Sigma) was also treated using the above-described procedure. 1 mM N ω -nitro-L-arginine methyl ester (L-NAME; a non-selective nitric oxide synthase inhibitor; Sigma) or 1 µM 1H-[1, 2, 4] oxadiazolo-4, 3-aquinoxalin-1-one (ODQ; NO-dependent guanylyl cyclase cGMP cascade inhibitor; Sigma) was used to inhibit the effect of NO. In addition, 50 µM z-VAD-fmk (a cell-permeable pancaspase inhibitor; Promega) or 5 µM z-DEVD-fmk (a cell-permeable caspase 3 specific inhibitor; Calbiochem, San Diego, CA) was used to block caspase activation. 20 µM of calpeptin (Calbiochem) or 10 µM of ALLM (a calpain inhibitor II; Calbiochem) was used as calpain inhibitors.
These inhibitors were pretreated one hour before the treatment with 4-bromo-calcium ionophore A23187 or GSNO.
Immunofluorescence staining and the quantitative assessment of cells containing aggregates
Transfected cells grown on glass coverslips were fixed for 20 min with 4% paraformaldehyde in PBS at room temperature and rinsed briefly with PBS. After fixation, they were permeabilized in 0.2% Triton X-100 (Sigma) and treated with 4% normal goat serum (Vector Laboratory, Burlingame, CA) for 1 h. To investigate the expression of human SOD1 protein, cells were treated at 4 o C overnight at a dilution of 1:300 with antibody specific to human SOD1 (Sigma). To induce SOD1 immunofluorescence, cells were incubated at a dilution of 1:300 with Bodipy FL anti-mouse IgG (Molecular Probes, Eugene, OR) at room temperature for 2 h. The characteristics of SOD1 aggregates in cells were examined either under an Olympus fluorescence microscope or a confocal microscope Zeiss LSM 5 Pascal. Quantitative analysis of cells containing SOD1 aggregates was performed under a fluorescence microscope using a 20× objective. Over 200 transfected cells on duplicate coverslips were assessed in three independent experiments. The distribution of SOD1 in cells was categorized as diffuse or aggregated. Most immunoreactive protein in cell bodies was observed in aggregates ( Figure 1A ). To score cells with SOD1 aggregates, six random microscopic fields were counted per coverslip. The microscopic fields to measure were blindly selected in coded slides. The selected showed dispersed or perinuclear aggregation (bar = 10 µm). (B) Mutated human SOD1 (hSOD) G93A, was transfected, and its protein expression was confirmed in addition to mouse SOD1 (mSOD). (C) Treatment with 1 µM A23187 (a 4-bromo-calcium ionophore) increased the number of cells containing G93A SOD1 aggregates, whereas other intracellular calcium release agents (10 µM cyclic ADP ribose, 10 nM ryanodine, or 10 µM thapsigargin) had no effect. (Data are means ± SEM. **P ＜ 0.01, versus the corresponding untreated controls or treated groups, as determined by the Student's t test, n = 5).
areas showing significant differences in total cell counts were excluded. Frequencies of intracytoplasmic aggregate-containing cells were defined as number of cells with aggregates divided by the number of SOD1-positive cells.
SOD activity assays
SOD activities were assayed as previously described (Misura and Fridovich, 1972) . Activities were measured at 30 o C by determining the rate inhibiting epinephrine auto-oxidation in 50 mM sodium carbonate buffer (pH 10.2) and 30 µl 10 mM epinephrine to give a slope of 0.025 absorbance units/min at 480 nm. The amount of SOD in a sample required to inhibit the rate of epinephrine auto-oxidation by 50% was defined as one unit of activity, and is expressed in units/mg of protein.
Western blot analysis
Total proteins from transfected cells were extracted with RIPA buffer (25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 137 mM NaCl, 1% TritonX-100, 1% sodium deoxycholate, 0.1% SDS) containing protease inhibitor cocktail tablets (Roche, Mannheim, Germany). Protein concentrations were determined using the Bradford method (Bio-Rad, Richmond, CA) using BSA as a standard. Proteins (30 µg/ lane) were separated in SDS-polyacrylamide separating gels and blotted onto nitrocellulose. Blots were probed overnight at 4 o C with anti-SOD 1 monoclonal antibody diluted to 1:500 (Sigma), anti-nNOS polyclonal antibody diluted 1:500 (Transduction Lab, Franklin lakes, NJ), or anti-nitrotyrosine antibody diluted 1:500 (Upstate, Charlottesville, VA), respectively. Anti-α -tubulin monoclonal antibody (clone DM 1A; 1:500, Neomarker, Fremont, CA) was used to compare protein loadings. Bands were visualized by chemiluminescence (Supersignal, Pierce, Rockford, IL).
Caspase 3 activity assays
Caspase 3 activities were determined by following specific cleavage at the C-terminal of the aspartate residue of the amino acid sequence DEVD (AspGlu-Val-Asp) by caspase 3. Cells (2×10 6 /dish) plated on a 60-mm dish (Falcon) were grown in culture medium until 80-90% confluent. Activity was measured using a Caspase TM assay system (Promega, Madison, WI), according to the manufacturer's instructions. In brief, treated cells were suspended in cell lysis buffer at 10 6 cells/ml and then lysed by freezing and thawing. Equal concentrations of lysates were incubated for 4 h at 37 o C with caspase assay buffer (312.5 mM HEPES, 31.25% sucrose, 0.3125% 3-[(3-cholamidopropyl)-dimethylammonio]-1 propane-sulfonate; CHAPS), DMSO, 10 mM DTT and colorimetric substrate (Ac-DEVD-pNA). Absorbances were measured at 405 nm.
Statistical analysis
Data are presented as means ± SEM and were analyzed using the Student's t test. Statistical significance was established at P ＜ 0.05. All experiments were repeated three times.
Results

Mutant SOD1 aggregates in VSC4.1 cells
In previous studies, aggregates of SOD1 were observed in the cytoplasm of cultured primary motor neurons expressing several different SOD1 mutants (Durham et al., 1997) . In the present study, immunocytochemistry with antibody specific to human SOD1 revealed that mutant SOD1 aggregation was present in the cytoplasm of VSC 4.1 cells. Diffuse dispersed and perinuclear aggregations were frequently observed. The overexpression of human SOD1 protein was confirmed by Western blotting, and the size of protein different from that of endogenous mouse SOD1 in VSC 4.1 cells ( Figure 1A and B). with 50 µM z-VAD-fmk prior to exposure to 1 µM A23187 decreased the number of cells containing aggregates, whereas 5 µM z-DEVD-fmk (a caspase 3 specific inhibitor) was ineffective. (B) Caspase 3 activities, as determined by Ac-DEVD-pNA cleavage (a colorimetric substrate) were not altered. (C) Pretreatment with calpain inhibitor (20 µM calpeptin) or calpain inhibitor II (10 µM ALLM) reduced the increased number of cells containing aggregates after 1 µM A23187 treatment (the data shown are means ± SEM). **P ＜ 0.01, *P ＜ 0.05, versus the corresponding untreated controls or treated groups, as determined by the Student's t test, n = 5).
Calcium influx increased aggregate formation
To determine whether an increase in intracellular calcium affects the formation of mutant SOD1 aggregates, the 4-bromo-calcium ionophore A23187 (1 µM) or other intracellular calcium releasers, namely, cyclic ADP ribose (10 µM), ryanodine (10 nM), or thapsigargin (10 µM) were added to cells after transfection with mutant SOD1. Treatment with A23187 increased SOD1 aggregation in cells, whereas the other intracellular calcium release agents did not (P ＜ 0.01) ( Figure 1C) . To evaluate the possibility that A23187 alters the expression or activity of mutant SOD1, we examined levels of mutant SOD1 expression and activity. A23187 treatment did not change the expression level of SOD1 or its activity (Figure 2A and B).
Calcium influx-induced NO generation increased aggregate formation
A23187 increased NO generation in VSC 4.1 cells expressing mutant SOD1 (Kim et al., 2002) . We observed that A23187 treatment increased nNOS expression in cells containing transfected mutant SOD1 ( Figure 2C ). To further investigate whether NO is involved in SOD1 aggregation, the transfected cells were treated with 1 mM L-NAME (a non-selective NOS inhibitor) or 1 µM ODQ (a NO-dependent cyclic GMP cascade inhibitor), which attenuated aggregate formation (P ＜ 0.05) ( Figure 2D ). Moreover, when cells were treated with exogenous GSNO it increased mutant SOD1 aggregation, and pretreatment with L-NAME and ODQ attenuated this effect of GSNO (P ＜ 0.01) (Figure 4 ). 
Calpain or caspase activation and aggregate formation
The formation of mutant SOD1 aggregates has been previously linked with apoptotic cell death (Durham et al., 1997) . Thus, we evaluated the involvements of caspase and calpain on SOD1 aggregate formation. A23187-induced mutant SOD1 aggregation was suppressed by z-VAD-fmk (a broad-spectrum caspase inhibitor), but not by z-DEVD-fmk (a caspase 3 inhibitor) ( Figure 3A) . Moreover, the activation of caspase 3 was not altered by calcium ionophore treatment ( Figure  3B ). Calpeptin or ALLM (both calpain inhibitors) reduced mutant SOD1 aggregation (P ＜ 0.05) ( Figure 3C ), but aggregation induced by exogenous NO was not attenuated by these calpain inhibitors (Figure 4 ).
Discussion
The results obtained during the present study demonstrate that calcium-influx, not induced by endogenous calcium releasers, increases the formation of mutant SOD1 aggregates via NO production.
A shared histological feature of many neurodegenerative diseases is the accumulation of misfolded proteins that trigger cell death signaling pathway (Kang et al., 2007) . Calcium-influx induced by motoneuronal AMPA receptors was found to promote the misfolding of mutant SOD1 protein and neuron death (Roy et al., 1998; Tateno et al., 2004) , and the inhibition of L-type voltagegated calcium channels or NMDA receptors partially prevented the aggregation and toxic effect of mutant SOD1 (Roy et al., 1998) . Calcium ionophore has been known to potentiate a response of neuron to NMDA (Markram and Segal, 1991) . In addition, calcium ionophore treatment was found to lead to an increase in cytosolic calcium by influx from the extracellular environment (Reed and Lardy, 1972; Qian et al., 1999) and efflux from vesicles in the endoplasmic reticulum (ER), and thus, this ionophore could be used to mimic the effects of IP 3 (Pressman, 1976) . In the present study, only the calcium ionophore A23187 increased aggregate formation. The other intracellular calcium releasers, namely, cyclic ADP ribose, ryanodine, and thapsigargin did not affect SOD1 aggregation, demonstrating that calcium-influx plays a primary role in aggregate formation, whereas endogenous calcium release does not. Exogenous calcium-influx does not affect SOD1 enzyme activity or protein expression according to our data, which suggests that aggregate formation is not mediated by an altered SOD1 protein level or SOD1 activity.
Oxidative stress resulting from an increased intracellular calcium level induced the misfolding of SOD1 within motoneurons (Carriedo et al., 2000; Tateno et al., 2004) . A cytoplasmic calcium overload can increase the production of reactive oxygen species via several mechanisms, e.g., the conversion of xanthine dehydrogenase to xanthine oxidase (Atlante et al., 1997) , the activation of PLA 2 (Chan and Fishman, 1980) , superoxide production by mitochondria (Castilho et al., 1995) , and the activation of NOS (Yun et al., 1996) . Moreover, it was found that calcium influx via calcium ionophore stimulated NO production by calmodulin-dependent constitutive NOS (Markram and Segal, 1991) . Previously, we showed that calcium ionophore increased NO generation significantly more than endogenous calcium release agents in motor neuronal cells expressing mutant SOD1 (Kim et al., 2002) . In the present study, we found that nNOS is involved in calcium influxinduced aggregate formation. nNOS is constitutively expressed in neurons and activated by intracellular calcium upregulation (Blottner and Luck, 2001) . Alterations in nNOS expression have also been reported in ALS (Anneser et al., 2001; Guegan and Przedborski, 2003) . Treatment with NOS inhibitor decreased aggregate formation in cells containing mutant SOD1 (Hyun et al., 2003) .
Moreover, the co-localization of NOS and SOD1 was observed in neurofilament aggregates in fALS, and sequestration of nNOS to neurofilament aggregates enhanced NMDA-mediated calcium influx (Sanelli et al., 2004) . However, the underlying mechanism as to how NOS increases aggregation formation is unknown. In the present study, the formation of SOD1 aggregates was attenuated by inhibiting NOS or the NO-dependent guanylyl cyclase cGMP cascade, which indicates that calcium influx-induced SOD1 aggregation, is mediated by NO.
In the present study, it was found that caspase or calpain is also involved in aggregate formation. Cultured motor neurons expressing mutant SOD1 and positive for apoptosis also contained SOD1 aggregates (Durham et al., 1997) . Moreover, motor neuron death in ALS was found to be associated with the activations of various caspases, e.g., caspase-1, caspase-3 and caspase-9 (Ekegren et al., 1999; Li et al., 2000; Pasinelli et al., 2000) . Increased aggregation by calcium influx can be attenuated by treating with z-VAD-fmk. However, z-DEVD-fmk was not effective and the activity of caspase 3 was unchanged in cells containing mutant SOD1 aggregates, which suggests that caspases other than caspase 3 may mediate aggregate formation. In addition, we observed that calpain inhibition was also effective at preventing calcium influx-induced SOD1 aggregation. Calpains are ubiquitously expressed in various cell types, including motoneurons (Suzuki et al., 1987) , and may be activated in the presence of elevated levels of intracellular calcium or by autolytic processing, to cleave many cellular targets, such as, transcription factors, and signal transduction and cytoskeletal proteins. Calpains also activate the caspases that mediate apoptosis by triggering the degradation of the cytochrome c-binding protein apoptotic protease activating factor-1 (apaf-1) (Roberts-Lewis et al., 1993; Reimertz et al., 2001) . Our data suggest that calcium influx induced calpain activation and that it played a role in the formation of mutant SOD1 aggregates.
Chronic exposure to glutamate increased the number of non-motor neurons expressing nNOS. It has been reported that under pathological conditions, reactive astrocytes or activated microglial cells produces NO, which has a toxic effect on surrounding cells (Nathan and Xie, 1994) . In the present study, it was found that exogenous NO increases mutant SOD1 aggregation. However, unlike calcium influx-induced mutant SOD1 aggregation, calpain inhibitors did not attenuate exogenous NO-induced aggregation. The above findings suggest that extracellular NO upregulation may have a toxic effect and induce the formation of mutant SOD1 aggregates via a mechanism that differs from NO formation by calcium influx. Further studies are needed to verify our findings.
